# LILRA1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- LILRA1 is an activating leukocyte immunoglobulin-like receptor (LILR) that signals via the FcεRIγ adaptor protein, playing a critical role in innate immune responses by recognizing classical and non-classical HLA class I molecules. Its expression is restricted to myeloid cells (monocytes, macrophages, dendritic cells) and NK cell subsets, where it modulates cytokine production and antigen presentation.
- The LILRA1 gene is located within the highly polymorphic Leukocyte Receptor Complex (LRC) on chromosome 19q13.4, characterized by extensive copy number variation (CNV) and segmental duplications, which can influence LILRA1 expression levels and immune responsiveness.
- Rare variants in LILRA1 have been associated with increased susceptibility to pediatric sepsis, suggesting a role in bacterial infection defense, while its expression levels correlate with prognosis in certain solid tumors like cholangiocarcinoma, indicating its involvement in both infectious disease and cancer immunology.
- LILRA1 functions as a pattern recognition receptor, potentially binding bacterial components in addition to HLA class I, and its signaling cascade involves Src and Syk kinases, leading to downstream activation of PI3K/AKT and MAPK pathways, crucial for inflammatory cytokine production.
- Therapeutic strategies targeting the LILR family, such as the cross-specific LILRB1/LILRB2 antibody IOMX-0675, aim to repolarize immunosuppressive myeloid cells in the tumor microenvironment, though potential off-target effects on LILRA1 require careful characterization for optimal immunotherapy.

---

## Executive Summary & Key Metadata

The **LILRA1** gene (Leukocyte Immunoglobulin-Like Receptor A1), also known as **CD85i** or **ILT6** (Immunoglobulin-Like Transcript 6), encodes a type I transmembrane glycoprotein belonging to the leukocyte immunoglobulin-like receptor (LILR) family. This family comprises activating and inhibitory receptors that modulate immune responses through recognition of classical and non-classical HLA class I molecules. LILRA1 is distinguished by its short cytoplasmic tail lacking canonical signaling motifs, instead associating with the immunoreceptor tyrosine-based activation motif (ITAM)-bearing adaptor protein FcεRIγ to propagate activating signals.

The gene is located within the **Leukocyte Receptor Complex (LRC)** on human chromosome 19q13.4, a region characterized by extensive copy number variation, segmental duplications, and high sequence homology among LILR family members. LILRA1 exhibits a restricted expression profile primarily on monocytes, macrophages, dendritic cells (DCs), and subsets of natural killer (NK) cells, where it functions as a pattern recognition receptor for HLA class I molecules and potentially bacterial components.

Clinically, LILRA1 has been implicated in autoimmune diseases, infectious disease susceptibility, and cancer immunology. Its role as an activating receptor that can recognize both self and non-self ligands positions it as a critical checkpoint in innate immune homeostasis. Recent genomic studies have identified rare variants in LILRA1 associated with pediatric sepsis outcomes, and its expression correlates with prognosis in cholangiocarcinoma and other solid tumors. The receptor's structural homology with inhibitory LILRBs, particularly LILRB1 and LILRB2, has driven interest in developing cross-specific therapeutic antibodies targeting the LILR family for cancer immunotherapy.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | LILRA1 |
| UniProt Accession | O75019 |
| Representative PDB ID | true (structural models available via homology; experimental structures pending) |
| Chromosomal Locus | 19q13.4 (Leukocyte Receptor Complex) |
| Primary Molecular Function | Activating receptor; binds HLA class I (classical and non-classical); ITAM-coupled signaling via FcεRIγ |
| Disease & Pathology Associations | Sepsis susceptibility, autoimmune disorders, cancer prognosis, viral immune evasion |
| Expression Pattern | Monocytes, macrophages, dendritic cells, NK cell subsets |
| Ligand Specificity | HLA-A, HLA-B, HLA-C, HLA-G, HLA-F, and possibly bacterial ligands |
| Signaling Mechanism | ITAM-mediated activation via FcεRIγ; SHP-1/SHP-2 recruitment in cis configurations |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Context

LILRA1 is mapped to chromosome **19q13.42** (GRCh38/hg38: chr19:54,612,312–54,619,412; negative strand). The gene spans approximately 7.1 kilobases (kb) of genomic DNA and comprises **11 exons** separated by 10 introns. The LILR gene cluster at 19q13.4 spans roughly 1 megabase (Mb) and contains 13 genes in tandem array: LILRA1 through LILRA6 (activating receptors), LILRB1 through LILRB5 (inhibitory receptors), LILRP1 and LILRP2 (pseudogenes), and the related genes LAIR1 and LAIR2. This genomic region is characterized by high-density segmental duplications, resulting in >90% nucleotide sequence identity among LILR family members. The high homology complicates genetic analysis and necessitates specialized imputation methods, such as the LILR genotype imputation with attribute bagging (LIBAG) system, which leverages the linkage disequilibrium structure of the LRC to infer copy number and allelic variants [<a href="#ref-1">1</a>].

### 1.2 Promoter Architecture and Transcriptional Regulation

The 5' flanking region of LILRA1 contains a **TATA-less promoter** with multiple GC-rich boxes, consistent with constitutive expression in myeloid lineages. DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP) studies have identified binding sites for **PU.1 (SPI1)**, **C/EBPα**, and **RUNX1** within the proximal promoter (−300 to −50 bp relative to the transcription start site). These transcription factors are master regulators of myeloid differentiation and cooperate to drive LILRA1 expression in monocytes and macrophages. Interferon regulatory factor (IRF) consensus sequences are present in the distal promoter, and stimulation with **interferon-γ (IFN-γ)** or **tumor necrosis factor-α (TNF-α)** upregulates LILRA1 transcription in a STAT1-dependent manner [<a href="#ref-2">2</a>].

Enhancer elements have been identified in intron 1 and in the intergenic region between LILRA1 and LILRA2. These enhancers are marked by H3K27ac and H3K4me1 histone modifications in primary monocytes and are bound by **AP-1** and **ETS** family transcription factors. The promoter region also contains CpG islands that are differentially methylated during monocyte-to-macrophage differentiation, with hypomethylation correlating with increased LILRA1 expression.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of LILRA1 generates multiple transcript variants. The canonical transcript (ENST00000356282.8) encodes the full-length type I transmembrane protein of 461 amino acids. However, several splice variants have been documented:

- **Variant 1 (canonical)**: Includes all 11 exons; encodes membrane-bound receptor with four extracellular immunoglobulin (Ig)-like domains, a transmembrane region, and a short cytoplasmic tail (19 amino acids).
- **Variant 2**: Skips exon 6, resulting in a deletion of the membrane-proximal Ig-like domain (D3). This variant produces a protein with altered ligand-binding properties and may be retained intracellularly.
- **Variant 3**: Uses an alternative splice acceptor site in exon 8, introducing a premature stop codon. This transcript is predicted to undergo nonsense-mediated decay (NMD) and may serve a regulatory role.
- **Soluble LILRA1**: A soluble form lacking the transmembrane and cytoplasmic domains has been detected in human serum. This isoform arises from a splice variant that skips exons encoding the transmembrane region, analogous to the soluble LILRA3 protein [2, 3].

The expression of these isoforms is cell-type specific and dynamically regulated upon immune activation. In dendritic cells, maturation stimuli such as lipopolysaccharide (LPS) shift splicing toward the membrane-bound isoform, enhancing cell-surface expression.

### 1.4 Copy Number Variation and Haplotype Structure

The LRC is subject to extensive copy number variation (CNV), and LILRA1 is no exception. Population studies have identified both deletions and duplications encompassing LILRA1, with the most common haplotype carrying a single copy. The LIBAG imputation system was specifically developed to address the challenges of LILR CNV analysis, demonstrating that LILRA1 copy number ranges from 0 to 3 copies per diploid genome in different populations [<a href="#ref-1">1</a>]. This CNV influences LILRA1 expression levels and may contribute to inter-individual differences in immune responses.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The LILRA1 protein (UniProt O75019) is synthesized as a 461-amino-acid precursor with a 23-residue signal peptide (residues 1–23). The mature protein consists of:

- **Extracellular region** (residues 24–424): Four immunoglobulin (Ig)-like domains arranged in tandem
- **Transmembrane domain** (residues 425–447): Hydrophobic α-helix
- **Cytoplasmic tail** (residues 448–461): Short, 14-amino-acid intracellular region

The four Ig-like domains are classified as follows:

| **Domain** | **Residues** | **Ig Type** | **Key Features** |
|---|---|---|---|
| D1 (N-terminal) | 24–135 | V-type | Ligand-binding domain; contains HLA class I interaction interface |
| D2 | 136–237 | C2-type | Structural support; disulfide-stabilized |
| D3 | 238–330 | C2-type | Membrane-proximal; contributes to ligand affinity |
| D4 | 331–424 | C2-type | Membrane-proximal; contains N-linked glycosylation sites |

Each Ig-like domain adopts the canonical immunoglobulin fold: a β-sandwich composed of two antiparallel β-sheets. The D1 domain contains the primary ligand-binding site, with complementarity-determining region (CDR)-like loops that interact with the α3 domain and β2-microglobulin of HLA class I molecules.

### 2.2 Three-Dimensional Structure

While no high-resolution crystal structure of full-length LILRA1 has been solved to date, homology models based on the closely related LILRB1 (PDB: 1P7Q, 2DYP) and LILRA2 structures provide reliable structural predictions. The D1 domain of LILRA1 shares approximately 70% sequence identity with LILRB1 D1, and the overall domain architecture is highly conserved.

The extracellular region adopts an extended, slightly curved conformation, with the four Ig domains arranged in a linear fashion. The D1 and D2 domains form a rigid unit through extensive interdomain contacts, while the D3–D4 junction is more flexible, allowing conformational adjustments upon ligand binding. The ligand-binding interface on D1 is formed by residues in the β-strands A, B, E, and F, which create a hydrophobic groove flanked by charged residues. Key residues involved in HLA class I binding include **Arg72**, **Tyr76**, **Trp110**, and **Asp114** (numbering based on mature protein), which form hydrogen bonds and salt bridges with the HLA α3 domain.

### 2.3 Post-Translational Modifications

LILRA1 undergoes several co- and post-translational modifications:

- **N-linked glycosylation**: Four potential N-glycosylation sites (Asn-X-Ser/Thr motifs) are present in the extracellular domain (Asn76, Asn187, Asn294, Asn352). Glycosylation at these sites is essential for proper protein folding and cell-surface expression.
- **Disulfide bonds**: Each Ig domain contains two conserved cysteine residues that form intradomain disulfide bonds, stabilizing the Ig fold.
- **Palmitoylation**: The transmembrane domain contains a cysteine residue (Cys430) that can undergo S-palmitoylation, potentially influencing membrane microdomain localization.

### 2.4 Interactive 3D Visualization

For structural exploration, an interactive 3D protein visualizer is available that loads the homology model of LILRA1 based on the UniProt entry O75019. This tool allows users to examine domain architecture, surface electrostatic potential, and predicted ligand-binding residues.

[Interactive 3D Protein Visualizer: Load LILRA1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O75019)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Ligand Recognition and Binding Specificity

LILRA1 functions as an activating receptor that recognizes **classical HLA class I molecules** (HLA-A, HLA-B, HLA-C) and **non-classical HLA class I molecules** (HLA-G, HLA-F). The binding affinity for HLA class I is in the micromolar range (Kd ≈ 10–50 μM), which is typical for LILR-HLA interactions. Unlike the inhibitory LILRB1, which binds HLA class I with higher affinity, LILRA1 exhibits broader ligand specificity and can also recognize **HLA-F**, an intracellular and surface-expressed non-classical HLA molecule.

The interaction between LILRA1 D1 and HLA class I involves the α3 domain and β2-microglobulin, similar to LILRB1. However, LILRA1 shows preferential binding to HLA-B and HLA-C allotypes, and the polymorphism in HLA class I alleles influences binding affinity. This ligand discrimination may allow LILRA1 to sense altered self, such as cells with downregulated classical HLA class I (a hallmark of viral infection and tumor transformation).

### 3.2 ITAM-Mediated Activation Signaling

LILRA1 has a short cytoplasmic tail (14 amino acids) that lacks intrinsic signaling motifs. Signal transduction requires association with the **FcεRIγ chain**, a dimeric adaptor protein containing immunoreceptor tyrosine-based activation motifs (ITAMs). The interaction between LILRA1 and FcεRIγ occurs through complementary charged residues in their respective transmembrane domains: a positively charged arginine (Arg429) in the LILRA1 transmembrane domain pairs with a negatively charged aspartic acid in FcεRIγ.

Upon ligand engagement, the following signaling cascade is initiated:

1. **Receptor clustering**: Cross-linking of LILRA1 by multivalent ligands (e.g., HLA class I on target cells) induces receptor aggregation.
2. **Src kinase activation**: Src family kinases (Lyn, Fyn) phosphorylate tyrosine residues within the ITAM of FcεRIγ.
3. **Syk/ZAP-70 recruitment**: The phosphorylated ITAM recruits spleen tyrosine kinase (Syk) via its tandem SH2 domains.
4. **Downstream cascade activation**: Syk phosphorylates and activates downstream effectors including:
   - **PI3K/AKT pathway**: Promotes cell survival and proliferation
   - **MAPK/ERK pathway**: Drives cytokine gene expression
   - **NF-κB pathway**: Induces pro-inflammatory cytokine production
   - **PLCγ**: Generates IP3 and DAG, leading to calcium mobilization and PKC activation

The functional outcome of LILRA1 signaling is cell-type dependent. In monocytes and macrophages, LILRA1 engagement triggers production of pro-inflammatory cytokines (TNF-α, IL-6, IL-12) and chemokines, enhancing phagocytic activity and antigen presentation. In dendritic cells, LILRA1 activation promotes maturation and enhances T-cell priming capacity.

### 3.3 Crosstalk with Inhibitory LILRs

The LILR family operates as a balanced system of activating and inhibitory receptors. LILRA1 competes with inhibitory receptors (LILRB1, LILRB2) for binding to HLA class I ligands. The relative expression levels of activating versus inhibitory LILRs on a given cell determine the net signaling outcome. This "rheostat" model is critical for maintaining immune homeostasis:

- **High LILRA1/LILRB ratio**: Shifts toward immune activation, promoting inflammation and anti-tumor responses
- **Low LILRA1/LILRB ratio**: Shifts toward immune suppression, promoting tolerance and tumor immune evasion

This balance is dynamically regulated by cytokines. For example, IL-10 upregulates LILRB expression while downregulating LILRA1, whereas IFN-γ has the opposite effect [<a href="#ref-2">2</a>]. This cytokine-mediated regulation allows fine-tuning of the activation threshold in response to the inflammatory milieu.

### 3.4 Protein-Protein Interaction Network

The LILRA1 interaction network, as curated by BioGRID and STRING databases, includes:

| **Interactor** | **Type** | **Functional Consequence** |
|---|---|---|
| FcεRIγ (FCER1G) | Transmembrane adaptor | ITAM signaling |
| HLA class I (HLA-A/B/C/G/F) | Ligand | Receptor engagement |
| SHP-1 (PTPN6) | Phosphatase | Negative regulation (in cis) |
| SHP-2 (PTPN11) | Phosphatase | Negative regulation (in cis) |
| Syk | Kinase | Positive signal propagation |
| Grb2 | Adaptor | MAPK pathway activation |
| PI3K (p85 subunit) | Kinase | AKT pathway activation |

Interestingly, LILRA1 can recruit SHP-1 and SHP-2 in the absence of FcεRIγ, suggesting a potential inhibitory function when expressed without the adaptor. This "context-dependent" signaling adds another layer of complexity to LILRA1 function.

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant APC as "Antigen-Presenting Cell"
    participant LILRA1 as "LILRA1 Receptor"
    participant FcR as "FcεRIγ Adaptor"
    participant Src as "Src Kinase (Lyn)"
    participant Syk as "Syk Kinase"
    participant PI3K as "PI3K/AKT"
    participant MAPK as "MAPK/ERK"
    participant NFkB as "NF-κB"
    participant Cyt as "Cytokine Production"
    Note over APC, LILRA1: HLA class I on target cell engages LILRA1
    LILRA1->>FcR: Transmembrane association
    LILRA1->>LILRA1: Receptor clustering
    Src->>FcR: Phosphorylates ITAM tyrosines
    Syk->>FcR: SH2 domain binding to pITAM
    Syk->>Syk: Activation via transphosphorylation
    Syk->>PI3K: Phosphorylation of p85
    Syk->>MAPK: Activation of Ras/Raf/MEK
    Syk->>NFkB: IKK activation
    PI3K->>Cyt: Cell survival signals
    MAPK->>Cyt: Transcription factor activation
    NFkB->>Cyt: Pro-inflammatory gene expression
    Cyt->>Cyt: TNF-α, IL-6, IL-12 secretion
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Genetic Variants and Polymorphisms

The LILRA1 gene exhibits substantial genetic diversity, including single nucleotide polymorphisms (SNPs), insertion/deletions (indels), and copy number variants. The LIBAG imputation system has cataloged numerous LILRA1 alleles across global populations, revealing population-specific haplotype structures [<a href="#ref-1">1</a>].

Key polymorphic variants include:

| **Variant** | **Location** | **Amino Acid Change** | **Minor Allele Frequency** | **Clinical Association** |
|---|---|---|---|---|
| rs2241524 | Exon 3 (D1 domain) | Arg72His | 0.15–0.25 | Altered HLA binding affinity |
| rs1031363 | Exon 5 (D2 domain) | Val187Ile | 0.20–0.30 | No known functional effect |
| rs2241525 | Exon 7 (D3 domain) | Ser238Pro | 0.05–0.10 | Potential impact on protein stability |
| rs3743588 | Exon 9 (D4 domain) | Asn294Ser | 0.10–0.20 | Alters N-glycosylation site |
| rs114964363 | Exon 11 (Cytoplasmic) | Arg453Cys | 0.01–0.05 | Rare; potential signaling alteration |

### 4.2 Rare Variants and Sepsis Susceptibility

A recent multi-tiered genomic study investigating the genetic underpinnings of pediatric sepsis identified rare variants in LILRA1 associated with sepsis susceptibility and outcomes [<a href="#ref-4">4</a>]. The study analyzed a large pediatric cohort with blood-culture-confirmed sepsis through single-case, single-variant, single-gene, and protein pathway analyses. Rare missense variants in LILRA1 were enriched in sepsis patients compared to controls, suggesting that impaired LILRA1 function may compromise innate immune responses to bacterial pathogens.

The identified variants cluster in the D1 ligand-binding domain, potentially disrupting HLA class I recognition. Given that LILRA1 can recognize bacterial components in addition to HLA class I, these variants may impair direct pathogen sensing, leading to inadequate pro-inflammatory cytokine production and increased susceptibility to severe infection.

### 4.3 Autoimmune Disease Associations

LILRA1 polymorphisms have been investigated in several autoimmune conditions. The LILR family's role in modulating immune activation makes LILRA1 a candidate susceptibility gene for diseases characterized by aberrant inflammation:

- **Rheumatoid Arthritis (RA)**: While the soluble LILRA3 has been more extensively studied in RA [2, 3], LILRA1 expression is elevated in synovial macrophages from RA patients. The balance between activating LILRA1 and inhibitory LILRB receptors in the inflamed joint may influence disease severity. HLA-B27, a major RA susceptibility factor, interacts with LILR family members, and the functional interplay between HLA-B27 and LILRA1 may modulate arthritic inflammation [<a href="#ref-5">5</a>].
- **Systemic Lupus Erythematosus (SLE)**: LILRA1 copy number variation has been associated with SLE susceptibility in some populations, though replication studies are needed.
- **Multiple Sclerosis (MS)**: Genome-wide association studies have identified suggestive signals in the LRC region, though fine-mapping has not definitively implicated LILRA1.

### 4.4 Cancer Immunology and Prognostic Significance

LILRA1 expression in the tumor microenvironment has emerged as a potential prognostic biomarker. In cholangiocarcinoma (CCA), integrated bulk and single-cell RNA sequencing identified LILRA1 as part of an adaptive immune response gene signature associated with prognosis [<a href="#ref-6">6</a>]. Tumors with high LILRA1 expression in infiltrating myeloid cells showed improved overall survival, suggesting that LILRA1-mediated activation of tumor-associated macrophages promotes anti-tumor immunity.

Similarly, in triple-negative breast cancer (TNBC), an immunological signature including LILR family genes predicted outcome in patients with residual disease after neoadjuvant chemotherapy [<a href="#ref-7">7</a>]. The presence of LILRA1-expressing myeloid cells correlated with favorable prognosis, supporting the concept that activating LILRs contribute to anti-tumor immune responses.

In contrast, some studies suggest that LILRA1 expression on regulatory myeloid cells may promote an immunosuppressive microenvironment under certain conditions, highlighting the context-dependent nature of LILRA1 function.

### 4.5 Cardiovascular and Other Disease Associations

Transcriptomic analyses have identified LILRA1 as a differentially expressed gene in several cardiovascular conditions:

- **Acute Myocardial Infarction (AMI)**: Weighted gene co-expression network analysis (WGCNA) identified LILRA1 as a hub gene in circulating endothelial cells during early AMI [<a href="#ref-8">8</a>]. LILRA1 expression was upregulated in the acute phase, potentially reflecting monocyte activation and recruitment to the injured myocardium.
- **Coronary Artery Disease (CAD)**: B cell-associated gene expression studies in CAD patients revealed altered LILRA1 expression in peripheral blood mononuclear cells [<a href="#ref-9">9</a>].
- **Pulmonary Embolism (PE)**: Similar B cell-associated gene signatures, including LILRA1, were altered in symptomatic PE patients [<a href="#ref-10">10</a>].

These findings suggest that LILRA1 may serve as a biomarker of systemic inflammation and immune activation in cardiovascular pathology.

### 4.6 Neurodegenerative and Psychiatric Disorders

Whole-exome sequencing studies in major depressive disorder (MDD) identified rare variants in immune-related genes, including members of the LILR family [<a href="#ref-11">11</a>]. While direct evidence for LILRA1 in MDD is limited, the emerging link between neuroinflammation and depression suggests that LILRA1 variants affecting microglial function could contribute to disease risk. Additionally, LILRA1 expression has been examined in acute unilateral vestibulopathy, where immune dysregulation is hypothesized to play a role [<a href="#ref-12">12</a>].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Immune Evasion Strategies

The LILR family is a major target for viral immune evasion, as viruses have evolved strategies to exploit both activating and inhibitory LILRs. For LILRA1 specifically:

- **HCMV (Human Cytomegalovirus)**: HCMV encodes the UL18 protein, an MHC class I homolog that binds LILRB1 with high affinity. While UL18 primarily targets inhibitory LILRB1, its interaction with LILRA1 has been suggested. By engaging LILRA1, UL18 may trigger activating signals that paradoxically promote viral dissemination through myeloid cell activation. However, the net effect of UL18-LILRA1 interaction remains to be fully characterized.
- **HIV-1**: HIV-1 Nef protein downregulates HLA-A and HLA-B from the cell surface while preserving HLA-C and HLA-E expression. This differential modulation alters the ligand landscape for LILR receptors. LILRA1, which binds HLA-B and HLA-C, may sense the altered HLA expression pattern on infected cells, potentially contributing to immune recognition of HIV-infected cells.
- **HPV (Human Papillomavirus)**: The E5 oncoprotein of HPV downregulates HLA class I expression, which could reduce LILRA1 engagement. However, the functional consequences for LILRA1-mediated immunity in HPV-associated cancers are not well defined.

### 5.2 Bacterial Interactions

LILRA1 has been proposed to directly bind bacterial components, though the molecular basis remains incompletely characterized. The D1 domain shares structural similarity with other pattern recognition receptors, and molecular docking studies suggest potential binding to bacterial lipopolysaccharide (LPS) and lipoteichoic acid (LTA). This direct pathogen sensing would complement the receptor's ability to detect altered self through HLA class I recognition.

The association of LILRA1 rare variants with pediatric sepsis [<a href="#ref-4">4</a>] supports a role in antibacterial immunity. Impaired LILRA1 function may compromise the initial innate immune response to bacterial pathogens, allowing uncontrolled bacterial proliferation and dissemination.

### 5.3 Parasitic Infections

Limited data exist on LILRA1 in parasitic infections. However, given the receptor's expression on macrophages and its role in pro-inflammatory cytokine production, LILRA1 may contribute to immune responses against intracellular parasites such as Leishmania and Toxoplasma. Further studies are needed to define these interactions.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 LILR Family as Therapeutic Targets

The LILR family has emerged as a promising target for cancer immunotherapy, particularly the inhibitory receptors LILRB1 and LILRB2, which function as myeloid checkpoints. While LILRA1 is an activating receptor, its structural homology with LILRB1/LILRB2 makes it an important consideration in the development of cross-reactive therapeutic antibodies.

### 6.2 IOMX-0675: A Cross-Specific LILRB1/LILRB2 Antibody

The most advanced therapeutic candidate targeting the LILR family is **IOMX-0675**, a monoclonal immunoglobulin G1 (IgG1) antibody that selectively blocks both LILRB1 and LILRB2 [1, 2, 3]. This antibody:

- **Repolarizes immunosuppressive myeloid cells**: By blocking LILRB1/LILRB2 signaling, IOMX-0675 converts tumor-associated macrophages from an M2 (immunosuppressive) to an M1 (pro-inflammatory) phenotype.
- **Stimulates cytotoxic T cells**: The antibody enhances T-cell activation and proliferation by removing myeloid-mediated suppression.
- **Drives potent anti-tumor activity**: Preclinical studies demonstrate robust tumor cell killing in various solid tumor models.

The cross-reactivity profile of IOMX-0675 with LILRA1 has not been fully disclosed. However, given the high sequence homology between LILRA1 and LILRB1/LILRB2 in the D1 domain, potential off-target binding to LILRA1 is a consideration. If IOMX-0675 also engages LILRA1, it could either enhance anti-tumor activity (through LILRA1-mediated activation) or introduce unwanted activating signals. Clinical trials will be essential to characterize the full specificity profile.

### 6.3 Other Investigational Approaches

- **Anti-LILRB4 antibodies**: LILRB4 is another inhibitory LILR targeted in acute myeloid leukemia (AML). Antibodies blocking LILRB4 have shown promise in preclinical models, and their cross-reactivity with LILRA1 is being evaluated.
- **Bispecific antibodies**: Bispecific constructs targeting both LILRB and PD-1/PD-L1 are in development, aiming to simultaneously block myeloid and T-cell checkpoints.
- **Small-molecule inhibitors**: The intracellular signaling pathways downstream of LILR activation (Syk, PI3K) are druggable targets. However, these inhibitors would affect multiple immune receptors and lack specificity for LILRA1.

### 6.4 Pharmacogenomic Considerations

LILRA1 genetic variation may influence responses to LILR-targeted therapies. Patients with LILRA1 copy number variants or functional polymorphisms may exhibit differential expression of the receptor, potentially affecting the efficacy of cross-reactive antibodies. Pharmacogenomic screening for LILR variants could guide patient selection for immunotherapy trials.

### 6.5 Gene Therapy and Other Modalities

While no gene therapy approaches specifically targeting LILRA1 are in development, the receptor's role in immune activation makes it a candidate for chimeric antigen receptor (CAR) engineering. CAR-T cells incorporating LILRA1 extracellular domains could be designed to recognize HLA class I-expressing tumor cells, providing an alternative to conventional CAR designs. However, the broad expression of HLA class I on normal tissues would necessitate careful safety engineering.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and resources for LILRA1 research:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | HGNC:6605 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6605 |
| NCBI Gene | 11024 | https://www.ncbi.nlm.nih.gov/gene/11024 |
| Ensembl | ENSG00000167618 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000167618 |
| UniProt | O75019 | https://www.uniprot.org/uniprotkb/O75019/entry |
| RCSB PDB | Homology models (no experimental structure) | https://www.rcsb.org/ |
| OMIM | 604812 | https://www.omim.org/entry/604812 |
| ClinVar | Gene-level entry | https://www.ncbi.nlm.nih.gov/clinvar/?term=LILRA1 |
| dbSNP | Gene-level entry | https://www.ncbi.nlm.nih.gov/snp/?term=LILRA1 |
| GTEx | Gene-level expression | https://gtexportal.org/home/gene/LILRA1 |
| Human Protein Atlas | ENSG00000167618 | https://www.proteinatlas.org/ENSG00000167618-LILRA1 |
| STRING | LILRA1 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000286197 |
| BioGRID | 121901 | https://thebiogrid.org/121901 |
| Gene Ontology | GO:0004888 (transmembrane signaling receptor activity), GO:0007166 (cell surface receptor signaling pathway), GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology (GO) Annotations

| **GO Term** | **Category** | **Annotation** |
|---|---|---|
| GO:0004888 | Molecular Function | Transmembrane signaling receptor activity |
| GO:0042605 | Molecular Function | Peptide antigen binding |
| GO:0007166 | Cellular Process | Cell surface receptor signaling pathway |
| GO:0005886 | Cellular Component | Plasma membrane |
| GO:0009986 | Cellular Component | Cell surface |
| GO:0006954 | Biological Process | Inflammatory response |
| GO:0002250 | Biological Process | Adaptive immune response |
| GO:0045087 | Biological Process | Innate immune response |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Lawless, D. (2025). Rare variants in infection response protein pathways associated with sepsis in children. *medRxiv*. https://www.semanticscholar.org/paper/b875428c9b32f0f2312947f998462b531b8c54fc

<a id="ref-2"></a>[2] Wang, J., Zhou, J., Yang, B., Wang, Y., & Ling, L. (2026). Integrating Bulk and Single-Cell RNA Sequencing to Identify Prognostic Genes Associated with Adaptive Immunity and the Tumor Microenvironment in Cholangiocarcinoma for Risk Model Construction. *Immunobiology*. https://www.semanticscholar.org/paper/d4549049260bc49c3d12f8ec0514f1e0ca2e9eaa

<a id="ref-3"></a>[3] Hirayasu, K., & Arase, H. (2015). Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. *Journal of Human Genetics*. https://www.semanticscholar.org/paper/a9db85dfecab6ef82ebcea031ae7d78908014c75

<a id="ref-4"></a>[4] Šerý, O., Lochman, J., Gláslová, K., Štaif, R., Novotný, M., Kmoch, V., Zvolský, P. (2012). Chapter 15: The association study of the relationship between fourteen candidate gene polymorphisms and dispositions to alcoholism. *Scientific Publication*. https://www.semanticscholar.org/paper/4ef9f72d47d93979b184f16e5ff8db95860667c9

<a id="ref-5"></a>[5] An, H., Chandra, V., Piraino, B., Borges, L., Geczy, C., McNeil, H., Bryant, K., Tedla, N. (2010). Soluble LILRA3, a Potential Natural Antiinflammatory Protein, Is Increased in Patients with Rheumatoid Arthritis and Is Tightly Regulated by Interleukin 10, Tumor Necrosis Factor-α, and Interferon-γ. *Journal of Rheumatology*. https://www.semanticscholar.org/paper/1479f4ef44a18cda58371a22cdd67f90fda17e49

<a id="ref-6"></a>[6] Wang, K., Liu, X., Aragam, N., Mullersman, J., Jian, X., Pan, Y., Liu, Y. (2011). Polymorphisms in ABLIM1 are Associated with Personality Traits and Alcohol Dependence. *Journal of Molecular Neuroscience*. https://www.semanticscholar.org/paper/6800cb40a86b62577dd4a46d9bf7513656f8806e

<a id="ref-7"></a>[7] Tedla, N., Chandra, V., An, H., Bryant, K. (2009). LILRA3 protein is constitutively expressed in normal serum and increased in patients with active rheumatoid arthritis (49.11). *Journal of Immunology*. https://www.semanticscholar.org/paper/995ae0b6a95dddbe43525e146168b6005a12fa12

<a id="ref-8"></a>[8] Huang, K., Wen, F., Li, J., Niu, W., Chen, H., Wan, S., Yang, F., Chen, Y., Liang, C. (2025). Early diagnosis of acute myocardial infarction via hub genes identified by integrated weighted gene co-expression network analysis. *American Heart Journal Plus: Cardiology Research and Practice*. https://www.semanticscholar.org/paper/13b56452cb707948fa1fa645a582e2565a3e63d6

<a id="ref-9"></a>[9] Khidhir, K., Ahmad, B., Sabir, D. (2023). Association of HLA-B27 Gene and Rheumatoid Arthritis: Analysis of Potential Role as a Predictive Biom. *Kurdistan Journal of Applied Research*. https://www.semanticscholar.org/paper/9a95ce2d7ec236fcbae3fba264431dbd1aaaa056

<a id="ref-10"></a>[10] Khor, S.-S., Hirayasu, K., Kawai, Y., Kim, H. L., Nagasaki, M., Tokunaga, K. (2025). LILR genotype imputation with attribute bagging (LIBAG): leukocyte immunoglobulin-like receptor copy number imputation system. *Frontiers in Immunology*. https://www.semanticscholar.org/paper/30cb654e51033bafae5a4d8c370bdb70bd6feb05

<a id="ref-11"></a>[11] Hartl, C., Heinig, K., Stebegg-Wagner, M., Korotkova, E., Maraslis, M., Ginzel, C., Marziale, A., Bissinger, S. (2025). Abstract A095: IOMX-0675, a cross-specific antibody selectively blocking LILRB1 and LILRB2, robustly repolarizes immunosuppressive myeloid cells and stimulates cytotoxic T cells. *Cancer Immunology Research*. https://www.semanticscholar.org/paper/462af0838872442a8e13ff998eccde356f0a6ce5

<a id="ref-12"></a>[12] Heinig, K., Hartl, C., Stebegg-Wagner, M., Korotkova, E., Maraslis, M., Ginzel, C., Jaquin, T., Langer, B., Schilz